TY - JOUR T1 - Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders JF - medRxiv DO - 10.1101/2021.10.15.21264977 SP - 2021.10.15.21264977 AU - Marton König AU - Hilde Marie Torgauten AU - Mathias Herstad Øverås AU - Adity Chopra AU - Åslaug Rudjord Lorentzen AU - The Trung Tran AU - Siri Mjaaland AU - Ingeborg Sundsvalen Aaberge AU - Kjell-Morten Myhr AU - Stig Wergeland AU - Tone Berge AU - Hanne Flinstad Harbo AU - Øivind Fredvik Torkildsen AU - Trygve Holmøy AU - Elisabeth Gulowsen Celius AU - Ludvig Andre Munthe AU - John Torgils Vaage AU - Fridtjof Lund-Johansen AU - Gro Owren Nygaard Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/18/2021.10.15.21264977.abstract N2 - Importance Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to protect against coronavirus disease of 2019 (COVID-19) is recommended for patients with multiple sclerosis (pwMS). However, approximately 80% of all pwMS treated with anti-CD20 therapy (rituximab, ocrelizumab) or fingolimod have low or absent humoral immunity after vaccination with two doses of SARS-CoV-2 mRNA vaccines. The efficacy and safety of a third vaccine dose in this group is largely unknown.Objective To characterize the humoral immunogenicity and the safety of a third dose of mRNA-COVID-19 vaccine in anti-CD20-or fingolimod-treated pwMS with low or absent humoral immunity (i.e., anti-SARS-CoV-2 IgG <70 arbitrary units (AU) and <5 AU, respectively) after two vaccinations.Design, setting and participants 130 anti-CD20- or fingolimod-treated pwMS with low or absent humoral immunity despite full vaccination against SARS-CoV-2, received a third dose of SARS-CoV-2 mRNA vaccine. Humoral immunity (i.e., antibody response against SARS-CoV-2) and the frequency and characteristics of side-effects were analyzed in all participants.Exposures A third vaccine dose against SARS-CoV-2 with BNT162b2- or mRNA-1273-COVID-19 vaccine.Main outcomes and measures Patient- and treatment-specific variables were acquired using a digital questionnaire, the Norwegian Immunization Registry and hospital journals. Humoral immunity was assessed by measuring SARS-CoV-2 SPIKE receptor-binding domain (RBD) IgG response. Low/absent humoral immunity was assumed in cases of AU<70 after anti-SPIKE protein-based serology 3-5 weeks after revaccination.Results A third dose of SARS-CoV-2 mRNA vaccine increased anti-SARS-CoV-2 SPIKE RBD IgG levels significantly. The proportion of patients with assumed protective humoral immunity (anti-SARS-CoV-2 SPIKE RBD IgG > 70 AU) were 25% among patients using anti-CD20 therapy and 7% among those treated with fingolimod. No adverse events were registered during the study period.Conclusion and relevance A third dose of mRNA-COVID-19 vaccine was associated with significantly increased levels of anti-SARS-CoV-2 SPIKE RBD IgG, – and hence assumed protective humoral immunity - in anti-CD20- or fingolimod-treated pwMS with low or absent humoral immunity despite full vaccination. The effect of a third vaccine dose was limited and more prominent among those treated with anti-CD20 therapy.Competing Interest StatementM. Konig has received speaker honoraria from Novartis, Biogen and AstraZeneca. H.M. Torgauten has nothing to disclose. M.H. Overas has nothing to disclose. A. Chopra has nothing to disclose. A. Lorentzen research fundings from Sanofi. T. Tran has nothing to disclose. S. Mjaaland has nothing to disclose. I.S. Aaberge has nothing to disclose. K.M. Myhr has received unrestricted research grants to his institution; scientific advisory board and speaker honoraria from Biogen, Merck, Novartis, Roche and Sanofi, and has participated in clinical trials organized by Biogen, Merck, Novartis, Roche and Sanofi S. Wergeland has received speaker honoraria from and served on scientific advisory boards for Biogen, Janssen-Cilag, Sanofi and Novartis. T. Berge has received unrestricted research grants from Biogen Idec and Sanofi Genzyme. H.F. Harbo has received honoraria for lecturing or advice from Biogen, Merck, Roche, Novartis and Sanofi. O.F. Torkildsen has received speaker honoraria from and served on scientific advisory boards for Biogen, BMS, Jansen, Sanofi, Merck and Novartis. T. Holmoy has received speaker honoraria and/or unrestricted research grants from Biogen, Merck, Roche, Novartis, Sanofi and Bristol-Myers Squibb, and participated in clinical trials organized by Merck, Sanofi and Roche. E.G. Celius has received honoraria for lecturing and advice from Biogen, BMS, Janssen, Merck, Novartis, Roche and Sanofi. L.A. Munthe has nothing to disclose. J.T. Vaage has nothing to disclose. F. Lund-Johansen has nothing to disclose. G.O. Nygaard has nothing to disclose. Clinical TrialThis study was approved by and registered at the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT Number: 2021-003618-37)Funding StatementThis study received economical support and funding from the Coalition for Epidemic Preparedness Innovations (CEPI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Norwegian South-Eastern Regional Ethical Committee (Ref. Nr. 200631) and the Norwegian Medicines Agency (EudraCT Number: 2021-003618-37). All participants gave written, informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript. ER -